We are currently updating this section of the Guidelines based on the Food and Drug Administration’s Emergency Use Authorization for bamlanivimab plus etesevimab for the treatment of mild to moderate COVID-19 in certain outpatients. Until these updates are released, please see the COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of the Bamlanivimab Plus Etesevimab Combination for the Treatment of COVID-19.
Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
Last Updated: February 11, 2021
Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
|
|
---|---|
References
- Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33113295.
- Activ-Tico Ly- CoV555 Study Group, Lundgren JD, Grund B, et al. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33356051.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of casirivimab and imdevimab. 2020. Available at: https://www.fda.gov/media/143892/download. Accessed November 13, 2020.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33332778.